MECHELEN, BELGIUM--(Marketwire -09/03/12)- Galapagos NV (GLPGF)announcedtoday that its Board of Directors created 530,140 warrants under a newwarrantplan for the benefit of employees, directors and independent consultantsof theCompany and its subsidiaries.
On 3 September 2012, the Board of Directors of Galapagos approved the"WarrantPlan 2012" within the framework of the authorized capital. Under thiswarrantplan, 530,140 warrants were created, subject to acceptances.
The warrants created under Warrant Plan 2012 were offered on 3 September2012,mainly to employees of Galapagos and its subsidiaries and in secondaryorder toits directors and consultants. The offer of warrants to directors has beenpre-approved by the Extraordinary General Shareholders' Meeting held on22August 2012.
The warrants have an exercise term of eight years as of the date of theofferand have an exercise price of EUR14.19 (the average closing price of theshare onEuronext Brussels during the thirty days preceding date of the offer).Thewarrants are not transferable and can in principle not be exercised priorto theend of the third calendar year after the calendar year in which theyweregranted to the beneficiaries. Each warrant gives the right to subscribeto onenew Galapagos share. Should the warrants be exercised, Galapagos willapply forthe listing of the resulting new shares on a regulated stock market.Thewarrants as such will not be listed on any stock market.
To date, Galapagos' total share capital amounts to EUR143,770,414.14;the totalnumber of securities conferring voting rights is 26,577,554, which isalso thetotal number of voting rights (the "denominator"), and all securitiesconferringvoting rights and all voting rights are of the same category. The totalnumberof rights (warrants) to subscribe to not yet issued securities conferringvotingrights is 3,696,502, which equals the total number of voting rightsthat mayresult from the exercise of these warrants. Galapagos does nothave anyconvertible bonds or shares without voting rights outstanding.
About GalapagosGalapagos (GLPGF) (GLPYY) is a mid-sizeclinical stagebiotechnology company specialized in the discovery and development ofsmallmolecule and antibody therapies with novel modes-of-action. TheCompany isprogressing its JAK1 inhibitor GLPG0634, as well as one of the largestpipelinesin biotech, with four programs in development and over 30 discoveryprograms. The Galapagos Group has over 800 employees and operates facilitiesin sixcountries, with global headquarters in Mechelen, Belgium. Moreinfo at:www.glpg.com
This release may contain forward-looking statements, including,withoutlimitation, statements containing the words "believes,""anticipates,""expects," "intends," "plans," "seeks," "estimates," "may," "will,""could,""stands to," and "continues," as well as similar expressions. Suchforward-looking statements may involve known and unknown risks, uncertainties andotherfactors which might cause the actual results, financial condition,performanceor achievements of Galapagos, or industry results, to be materiallydifferentfrom any historic or future results, financial conditions,performance orachievements expressed or implied by such forward-looking statements.Giventhese uncertainties, the reader is advised not to place any unduereliance onsuch forward-looking statements. These forward-looking statements speakonly asof the date of publication of this document. Galapagos expresslydisclaims anyobligation to update any such forward-looking statements in thisdocument toreflect any change in its expectations with regard thereto or anychange inevents, conditions or circumstances on which any such statement is based,unlessrequired by law or regulation.
This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE[HUG#1638375]
Director Investor Relations
Tel: +31 6 2291 6240